Target intelligence / Profile preview

lncRNA-MYC inhibitory factor (lncRNA-MIF)

Target: lncRNA-MIF
Molecular classification: Long non-coding RNA (lncRNA), Regulatory RNA, Other

Overview

lncRNA-MIF (ODC1 divergent transcript) is a long non-coding RNA transcribed from a locus adjacent to the ODC1 gene, a well-known MYC target[2][4]. Its expression is directly upregulated by c-Myc, and it forms part of a feedback loop in which it enhances the expression of Fbxw7, an E3 ubiquitin ligase, by acting as a microRNA sponge for miR-586. This leads to increased proteasomal degradation of c-Myc protein and attenuates aerobic glycolysis and tumorigenesis, suggesting a tumor suppressor role[2][4][5]. lncRNA-MIF has been described primarily in cancer cell studies and may represent a regulatory layer controlling oncogene expression and metabolic reprogramming in tumors. Currently, there are no drugs targeting lncRNA-MIF and it is not used as a biomarker or therapeutic target, but its function in cancer metabolism and MYC regulation remains an area of active research.

Other names: ODC1 divergent transcript (ODC1-DT)lncRNA-MIFc-Myc inhibitory factorENST00000553181.5RP11-320M2.1

Biological functions

Negative regulation of c-Myc protein stability via upregulation of Fbxw7 (E3 ubiquitin ligase)Inhibition of glycolysisControl of cellular proliferation and tumorigenesisCompeting endogenous RNA (microRNA sponge for miR-586)

Disease associations

Cancer (regulation of c-Myc, involvement in tumor suppression and glycolysis, described in colorectal and other cancers)Other (regulation of cellular metabolism)

Beyond the preview

Go deeper on lncRNA-MYC inhibitory factor (lncRNA-MIF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lncRNA-MYC inhibitory factor (lncRNA-MIF).

Explore the full profile